Your browser doesn't support javascript.
loading
Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
Thomas, S; Laino, A; Sturm, R; Nufer, K; Lambie, D; Shepherd, B; Atkinson, V; Adams, L; Soyer, H P; Schaider, H.
Afiliação
  • Thomas S; Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia.
  • Laino A; Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
  • Sturm R; Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia.
  • Nufer K; Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
  • Lambie D; Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia.
  • Shepherd B; Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia.
  • Atkinson V; Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
  • Adams L; IQ Pathology, Brisbane, QLD, Australia.
  • Soyer HP; Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
  • Schaider H; Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
J Eur Acad Dermatol Venereol ; 32(5): e176-e177, 2018 May.
Article em En | MEDLINE | ID: mdl-29114959

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Melanoma Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Melanoma Idioma: En Ano de publicação: 2018 Tipo de documento: Article